Search

everythinglearnresearchcommunity

for

Search:↓

Analyzing data on pyrilutamide, a potential hair loss treatment, as well as the effectiveness of other treatments such as Minoxidil, Finasteride, and RU58841.

The potential release date for results from a phase 2 trial of Pyrilutamide, a hair loss treatment that combines Minoxidil, Finasteride and RU58841. It was agreed that the results are expected to be released in June 2022.

Vitamin D supplementation can aid hair regrowth for some, but results differ. Combining vitamin D with finasteride and minoxidil often improves hair thickness, though not for everyone.

Pyrilutamide shows minimal systemic absorption with low plasma levels and no accumulation, suggesting it's unlikely to cause systemic side effects. However, full results are not yet published in scientific journals.

Oral minoxidil can cause cardiovascular issues, but an extended release formulation may reduce side effects like heart rate and blood pressure spikes. This new formulation offers a safer option for those who previously had to stop due to health concerns.

There is an inconsistency between the molecular weight and formula listed on EveryChem's product page and the analytical PDFs for 3HP and PP30, suggesting a possible error in the product description. Concerns are raised about EveryChem's business practices and lack of transparency in testing and manufacturing.

Topical Clascoterone showed a 539% improvement in hair count compared to placebo, but its effectiveness and safety are debated. Users compared it to minoxidil and finasteride, with mixed opinions on its potential release in 2026 or 2027.

Combining Minoxidil with peptide serums like Redensyl, Procapil, and Capixyl is more effective for hair growth than using Minoxidil alone, increasing hair density and thickness. However, some users are skeptical about the effectiveness of peptides, suggesting other ingredients or factors might contribute to the results.

Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.

The conversation is about hair regrowth progress using Minoxidil and Finasteride. The user reports improved hair fallout but still experiences significant hair loss.

A user is considering stopping hair loss treatments, including finasteride, dutasteride, and minoxidil, due to lack of progress after 16 months. They plan to continue until October and are seeking advice and experiences from others.

The conversation is about gathering serum DHT data from individuals taking dutasteride to investigate its efficacy, especially in cases with unexpectedly low DHT reduction. The aim is to explore potential genetic factors affecting drug metabolism.

Dutasteride is safer than finasteride for long-term use, with fewer sexual side effects. Users experience better hair regrowth and fewer side effects with dutasteride.

Onion juice helped with hair loss but was smelly and inconvenient. The user now uses dutasteride and minoxidil, finding them more effective and practical.

The conversation discusses the potential release date of a hair loss treatment called Pyrilutamide. One user suggests it may be available in about 5 years.

Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.

This user has conducted data scraping of 365 Reddit posts on the hairloss drug Pyrilutamide over the last year to analyse efficacy and side effects. The findings, which are available in a 19 page report with graphs, suggest that 22% of Pyrilutamide users experience positive results while 63% experience symptoms. A larger analytics project is proposed for other drugs with enough demand.

Replicel's results were delayed, but Shiseido might share data at BioJapan on October 11. Users are hopeful for new treatments like RCH-01, potentially eliminating the need for finasteride or minoxidil.

The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It also references upcoming trial data from Shiseido in Japan.

Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.

Derek has maintained his hair for over a decade using dutasteride, keto shampoo, and previously minoxidil, despite early hair loss and family history of baldness. Other users discuss their own hair loss treatments, including combinations of oral minoxidil, finasteride, dutasteride, RU58841, nizoral, microneedling, and low-level laser therapy.

A user with stage 1 hair loss is inquiring about the release date of GT20029, hoping to use it instead of Minoxidil and finasteride, as they believe it has better results. They want to know if it will be available in the next couple of years.

A 23-year-old man started using Minoxidil for hair thinning and experienced improvement, which helped him gain the confidence to ask a girl out, resulting in a date. Other users congratulated him and discussed the importance of hair appearance in dating, with some suggesting other treatments like finasteride or hair transplants.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

The conversation is about a user trying a shampoo and conditioner recommended by Derek from More Plates More Dates to slow down hair loss. The products contain Ketoconazole, pumpkin seed oil, tea tree oil, peppermint oil, and biotin, and the user is satisfied with the results so far.

Hair loss discussion includes treatments Min, Fin, and RU. Kintor's KX-826 Phase 2 data release delayed to September due to COVID.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Pyrilutamide Phase 2 results are expected in June 2022, with hopes for a better alternative to current treatments.

Various hair loss treatments were tried, including coconut oil, dermarolling, finasteride, Zix, minoxidil, and RU58841. The most effective combination was RU58841 and minoxidil, which halted hair loss and thickened hair without significant side effects.

The conversation discusses promising hair cloning research seeking commercialization partners. Cultured hairs formed with pigment, indicating positive progress.

Regrowing hair with finasteride and minoxidil can boost confidence and improve dating prospects. However, confidence and personality are considered more important than appearance in relationships.